Immune checkpoint inhibitors-induced diabetes mellitus: a growing clinical presentation requiring our attention

Expert Opin Drug Saf. 2022 Nov;21(11):1337-1339. doi: 10.1080/14740338.2022.2134343. Epub 2022 Oct 11.
No abstract available

Keywords: Immune checkpoints; new-onset DM; safety; therapy.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antineoplastic Agents, Immunological*
  • Attention
  • Diabetes Mellitus*
  • Humans
  • Immune Checkpoint Inhibitors
  • Immunotherapy
  • Nivolumab

Substances

  • Immune Checkpoint Inhibitors
  • Nivolumab
  • Antineoplastic Agents, Immunological